

increased DNA binding. Baseline HSS score 6.5 ± 2.5 , PGA score 1.28 ± 0.54 , and CLASI activity score 8.7 ± 9.7 . 16 (42.1%) of the patients were Ro [SS-A] positive, and 15 (35.7%) were positive for antiphospholipid antibodies [aPL], which included lupus anticoagulant [LA], anticardiolipin [aCL] and antiphosphatidylserine [aPS] antibodies.

CC-220 as a Cereblon E3 ubiquitin ligase modulator binds to cereblon and facilitates Ikaros and Aiolos degradation. CC-220 inhibits plasmablast differentiation and reduces Ikaros (IKZF1) and Aiolos (IKZF3) protein levels in B-cells, T-cells, and monocytes.

Efficacy and safety outcomes as well as biomarker parameters are pending.

Conclusions CC-220 is a compound that modulates the Cereblon E3 ubiquitin ligase, resulting in reduction in Ikaros and Aiolos protein levels in B cells, T cells, and monocytes. The efficacy and safety of CC-220 in the treatment of SLE is currently being evaluated in a Phase 2 study.

Acknowledgements Abstract is being presented on behalf of the CC-220 study team.

Trial Registration NCT02185040

Clinical Epidemiology and Outcomes Research

CE-01 REMISSION IN SYSTEMIC LUPUS ERYTHEMATOSUS – DURABLE REMISSION IS RARE

¹Theresa Rita Wilhelm, ²Laurence S Magder*, ¹Michelle A Petri. ¹Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD; ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, USA

10.1136/lupus-2016-000179.80

Background Remission is the ultimate goal in SLE. In this study, we applied four definitions of remission agreed on by an international collaboration (DORIS) to a large clinical cohort.

Materials and methods We applied the DORIS definitions of Clinical Remission, Complete Remission (requiring negative serologies), Clinical Remission on Treatment (ROT) and Complete ROT. 2307 patients entered the cohort from 1987 to 2014. Patients not in remission at cohort entry were followed prospectively. We used the Kaplan-Meier approach. Cox regression was used to identify baseline factors associated with time to remission.

Results The median time to remission was 8.7, 11.0, 1.8 and 3.1 years for Clinical Remission, Complete Remission, Clinical ROT

and Complete ROT, respectively. High baseline treatment was the major predictor of a longer time to remission, followed by high baseline activity. The median duration of remission for all definitions was just three months. Based on Kaplan-Meier estimates, we determined the durability of remission by specified times as shown in Table 1. African-American ethnicity, baseline low C3 and baseline hematologic activity were associated with longer time to remission for all definitions. Baseline anti-dsDNA and baseline low C4 were associated with longer time to Complete Remission and Complete ROT. Baseline low C4 was also a negative predictor for Clinical Remission.

Conclusions These findings demonstrate that it was easier to reach ROT than remission. Baseline treatment and baseline disease activity were strongly associated with the time to remission for all definitions. We found that the durability of remission was very short, regardless of definition. African-American ethnicity, baseline low C3 and baseline hematologic activity were associated with a longer time to remission. Baseline anti-dsDNA and baseline low C4 were negative predictors for complete remission and for complete ROT. Our results provide further insights into the frequency and durability of remission in SLE and call attention to the major role of baseline activity and baseline treatment in predicting remission.

CE-02 PEER APPROACHES TO LUPUS SELF-MANAGEMENT (PALS): A NOVEL LUPUS PEER MENTORSHIP INTERVENTION

¹Edith Williams*, ²Leonard Egede, ³James Oates. ¹Department of Public Health Sciences, Medical University of South Carolina; ²Center for Health Disparities Research, Medical University of South Carolina; ³Division of Rheumatology and Immunology, Medical University of South Carolina

10.1136/lupus-2016-000179.81

Background Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that is associated with increased morbidity, mortality, health care costs and decreased quality of life. While evidence-based self-management interventions that incorporate both social support and health education have reduced pain, improved function, and delayed disability among lupus patients, African Americans and women are still disproportionately impacted by lupus. In the United States, African Americans have three to four times greater prevalence of lupus, risk of developing lupus at an earlier age, and lupus-related disease activity, damage, and mortality compared with Caucasians, with the highest rates experienced by African American women. Persistent disparities may be due to the non-responsiveness of existing programs to the unique needs of African Americans and/or women with lupus. Peer mentoring interventions are effective in other chronic conditions that disproportionately affect minorities, such as diabetes, HIV, and kidney disease, but there is currently no empirically tested peer mentoring intervention developed for SLE patients.

Materials and methods A literature review, needs assessment, and interviews with patients guided the development of a peer mentor training manual and a peer mentoring intervention. African American women with lupus are being recruited from the SLE database at the Medical University of South Carolina. Seven mentors will be trained and paired with 21 mentees to provide modelling and reinforcement to participants by telephone for at least 60 minutes every week for 12 weeks. The goal of mentorship will be to encourage mentees to engage in activities that promote the learning of disease self-management skills and to support the mentees' practice of these learned skills during the

Abstract CE-01 Table 1 Durability of remission in% by specified times

Duration	Clinical remission	Complete Remission	Clinical remission on treatment	Complete remission on treatment
120 days	43.8	41.0	44.5	4.03
240 days	24.3	21.3	22.7	18.6
1 year	13.2	12.1	13.4	9.3
2 years	5.6	5.2	5.6	3.6
5 years	1.2	2.0	0.6	0.7
10 years	0.4	1.3	0.3	0.7